202 related articles for article (PubMed ID: 19855158)
1. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation.
Araujo JC; Poblenz A; Corn P; Parikh NU; Starbuck MW; Thompson JT; Lee F; Logothetis CJ; Darnay BG
Cancer Biol Ther; 2009 Nov; 8(22):2153-9. PubMed ID: 19855158
[TBL] [Abstract][Full Text] [Related]
2. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
Id Boufker H; Lagneaux L; Najar M; Piccart M; Ghanem G; Body JJ; Journé F
BMC Cancer; 2010 Jun; 10():298. PubMed ID: 20565769
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
Garcia-Gomez A; Ocio EM; Crusoe E; Santamaria C; Hernández-Campo P; Blanco JF; Sanchez-Guijo FM; Hernández-Iglesias T; Briñón JG; Fisac-Herrero RM; Lee FY; Pandiella A; San Miguel JF; Garayoa M
PLoS One; 2012; 7(4):e34914. PubMed ID: 22539950
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
5. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.
Vandyke K; Dewar AL; Diamond P; Fitter S; Schultz CG; Sims NA; Zannettino AC
J Bone Miner Res; 2010 Aug; 25(8):1759-70. PubMed ID: 20225261
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
7. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Koreckij T; Nguyen H; Brown LG; Yu EY; Vessella RL; Corey E
Br J Cancer; 2009 Jul; 101(2):263-8. PubMed ID: 19603032
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
10. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
[TBL] [Abstract][Full Text] [Related]
11. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
[TBL] [Abstract][Full Text] [Related]
13. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
Araujo J; Logothetis C
Cancer Treat Rev; 2010 Oct; 36(6):492-500. PubMed ID: 20226597
[TBL] [Abstract][Full Text] [Related]
15. The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.
Appel CK; Gallego-Pedersen S; Andersen L; Blancheflor Kristensen S; Ding M; Falk S; Sayilekshmy M; Gabel-Jensen C; Heegaard AM
Sci Rep; 2017 Jul; 7(1):4792. PubMed ID: 28684771
[TBL] [Abstract][Full Text] [Related]
16. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts.
Woo JT; Nakagawa H; Notoya M; Yonezawa T; Udagawa N; Lee IS; Ohnishi M; Hagiwara H; Nagai K
Biol Pharm Bull; 2004 Apr; 27(4):504-9. PubMed ID: 15056855
[TBL] [Abstract][Full Text] [Related]
17. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
[TBL] [Abstract][Full Text] [Related]
18. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
19. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Sankar U; Patel K; Rosol TJ; Ostrowski MC
J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Osteoclast Differentiation at Multiple Stages by Protein Kinase D Family Kinases.
Leightner AC; Mello Guimaraes Meyers C; Evans MD; Mansky KC; Gopalakrishnan R; Jensen ED
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
